A Pharmacokinetic Study of an Experimental Paracetamol Formulation

Phase 1CompletedNCT01476176

GlaxoSmithKline30 enrolled

Overview

This PK study is designed to show bioequivalence between the study treatments.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

experimental paracetamol with caffeine

marketed formulation containing caffeine

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy volunteer Exclusion Criteria: \-

MDS Pharma Services ARIZONA

Phoenix, Arizona, United States

PK variables (AUC 0-10hrs, AUC 0-inf, and Cmax) to determine bioequivalence

Time frame: 10 hours

PK variables to compare speed of absorption (AUC 0-30min, AUC 0-60min, Tmax)

Time frame: 10 hours

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.